Table 4.
Predictors Of Serious Treatment Interruption By Univariate And Multivariate Analysis
| Characteristic | Total N (%) | Duration Of Interruption | P Value | Adjusted OR (95% CI) | P-Value (LR Test) | |
|---|---|---|---|---|---|---|
| 0–14 Days | >14 days | |||||
| Total | 202 (100.0) | 144 (71.3) | 58 (28.7) | |||
| Gender | 0.677 | – | – | |||
| Female | 67 (33.2) | 46 (31.9) | 21 (36.2) | |||
| Male | 135 (66.8) | 98 (68.1) | 37 (63.8) | |||
| Age (years) | 0.189 | 0.497 | ||||
| 14–25 | 47 (23.3) | 37 (25.7) | 10 (17.2) | Ref | ||
| 25–59 | 134 (66.3) | 95 (66.0) | 39 (67.2) | 1.23 (0.52–2.89) | ||
| ≥ 60 | 21 (10.4) | 12 (8.3) | 9 (15.5) | 2.06 (0.62–6.92) | ||
| Marital status | 0.355 | – | – | |||
| Single | 78 (38.6) | 59 (41) | 19 (32.8) | |||
| Married | 124 (61.4) | 85 (59) | 39 (67.2) | |||
| Education level | 0.578 | – | – | |||
| Primary school or less | 60 (29.7) | 43 (29.9) | 17 (29.3) | |||
| Middle school | 68 (33.7) | 49 (34.0) | 19 (32.8) | |||
| High school | 55 (27.2) | 41 (28.5) | 14 (24.1) | |||
| University | 19 (9.4) | 11 (7.6) | 8 (13.8) | |||
| Occupational status after diagnosis | 0.713 | – | – | |||
| Still working | 62 (30.7) | 45 (31.2) | 17 (29.3) | |||
| Lost job or could not work | 103 (51.0) | 71 (49.3) | 32 (55.2) | |||
| Student/unemployed | 37 (18.3) | 28 (19.4) | 9 (15.5) | |||
| In debt due to MDR-TB | 1.000 | – | – | |||
| Yes | 120 (59.4) | 86 (59.7) | 34 (58.6) | |||
| No | 82 (40.6) | 58 (40.3) | 24 (41.4) | |||
| Weight at baseline | 0.246 | – | – | |||
| ≥50kg | 119 (58.9) | 89 (61.8) | 30 (51.7) | |||
| <50kg | 83 (41.1) | 55 (38.2) | 28 (48.3) | |||
| Duration of treatment (months) | – | – | ||||
| 1–11 | 60 (29.7) | 41 (28.5) | 19 (32.8) | 0.665 | ||
| 12–24 | 142 (70.3) | 103 (71.5) | 39 (67.2) | |||
| Underwent DOT | 1 | – | – | |||
| Yes | 56 (27.7) | 40 (27.8)) | 16 (27.6) | |||
| No | 146 (72.3) | 104 (72.2) | 42 (72.4) | |||
| Monthly OOP drug expenses (US$) | 0.005 | 0.020 | ||||
| ≤ 250 | 145 (71.8) | 112 (77.8) | 33 (56.9) | Ref | ||
| >250 | 57 (28.2) | 32 (22.2) | 25 (43.1) | 2.27 (1.14–4.50) | ||
| Baseline co-morbidity | 0.002 | 0.017 | ||||
| No | 162 (80.2) | 124 (86.1) | 38 (65.5) | Ref | ||
| Yes | 40 (19.8) | 20 (13.9) | 20 (34.5) | 2.53 (1.19–5.38) | ||
| Any ADRs during treatment | <0.001 | 0.003 | ||||
| No | 98 (48.5) | 82 (56.9) | 16 (27.6) | Ref | ||
| Yes | 104 (51.5) | 62 (43.1) | 42 (72.4) | 2.82 (1.41–5.61) | ||
Abbreviations: ADRs, adverse drug reactions; DOT, directly observed treatment; MDR-TB, multidrug-resistant tuberculosis; OOP, out-of-pocket; OR, odds ratio; CI, confidence interval; LR test, likelihood ratio test; ref, reference group.